Prevention of pre-eclampsia by early antiplatelet therapy

Lancet. 1985 Apr 13;1(8433):840-2. doi: 10.1016/s0140-6736(85)92207-x.


102 patients at high risk of pre-eclampsia and/or fetal growth retardation were randomly allocated to treatment with 300 mg dipyridamole and 150 mg aspirin daily from 3 months' gestation onwards (group A) or to the control group (group B, no treatment). Group A was twice as likely as group B to have a normal pregnancy. Pre-eclampsia occurred in 6 patients in group B and none in group A. Major complications (fetal death or severe growth retardation) occurred in 9 patients in group B and none in group A. Platelet count and plasma volume were significantly higher in group A than in group B throughout pregnancy. The treatment did not produce serious adverse effects. Antiplatelet therapy given early in pregnancy to high-risk patients may thus protect against pre-eclampsia and fetal growth retardation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aspirin / therapeutic use*
  • Dipyridamole / therapeutic use*
  • Female
  • Humans
  • Pre-Eclampsia / prevention & control*
  • Pregnancy


  • Dipyridamole
  • Aspirin